In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .
Effect of folic acid supplementation on cancer risk among adults with hypertension in China: A randomized clinical trial
The relationship of folic acid supplementation with the risk of cancer remains inconclusive . We aim ed to evaluate the effects of folic acid supplementation on cancer incidence among adults with hypertension without history of stroke or myocardial infa rct ion ( MI ) in the China Stroke Primary Prevention Trial ( CSPPT ) . A total of 20,702 hypertensive adults without history of stroke or MI , stratified by MTHFR C677 T genotypes(CC , CT and TT ) , were r and omly assigned to receive double‐blind daily treatment with a single pill containing 10 mg enalapril and 0.8 mg folic acid(n = 10,348 ) or a pill containing 10 mg enalapril alone(n = 10,354 ) . During a median treatment duration of 4.5 years , cancer occurred in 116 participants ( 1.12 % ) in the enalapril‐folic acid group versus 116 participants ( 1.12 % ) in the enalapril group ( HR , 1.00 ; 95%CI , 0.77–1.29 ) . There was also no significant difference in the HRs for specific types of cancer(esophageal , gastric , breast , lung , colorectal , head and neck , liver and gynecologic cancer or lymphoma ) or cancer mortality(HR , 1.05 ; 95%CI , 0.69–1.58 ) . For participants not receiving folic acid treatment ( enalapril only group ) , MTHFR 677 TT genotype was an independent predictor of total cancer risk compared to CC genotype ( HR , 1.86 ; 95%CI , 1.07–3.22 ) . Consistently , a beneficial effect was observed in participants with MTHFR TT genotype and low folate levels ( < 9.0 ng/mL ; HR , 0.47 ; 95%CI , 0.24–0.94 ) . There is no evidence that 0.8 mg daily folic acid supplementation can increase the risk of cancer incidence among adults with hypertension without history of stroke or MI in China . Our data suggest a protective effect in participants with MTHFR TT genotype and low folate levels
In this third up date of the Cochrane review , there were no differences in effects of homocysteine-lowering interventions in the form of supplements of vitamins B6 , B9 or B12 given alone or in combination comparing with placebo on myocardial infa rct ion , death from any cause or adverse events .
BACKGROUND Cardiovascular disease , which includes coronary artery disease , stroke and peripheral vascular disease , is a leading cause of death worldwide .
Homocysteine is an amino acid with biological functions in methionine metabolism .
A postulated risk factor for cardiovascular disease is an elevated circulating total homocysteine level .
The impact of homocysteine-lowering interventions , given to patients in the form of vitamins B6 , B9 or B12 supplements , on cardiovascular events has been investigated .
This is an up date of a review previously published in 2009 , 2013 , and 2015 .
OBJECTIVES To determine whether homocysteine-lowering interventions , provided to patients with and without pre-existing cardiovascular disease are effective in preventing cardiovascular events , as well as reducing all-cause mortality , and to evaluate their safety .